Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Notified -
Globe Newswire24-02-2025, 13:00
Timeless travel with VistaJet and Valextra — two icons, one destination 29-06-2023, 16:39